원바이오젠
Financials
Valuation Metrics
원바이오젠's Market Cap is ₩386B. At end of 2025 it was ₩474B. Ranked #1908 of 2,436 in KR market (top 78%), #1190 of 1,649 on KOSDAQ (top 72%), #78 of 96 in Health Care Equipment & Services (top 81%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 38.59B KRW | KR#1,908/2,436 Sec#78/96 |
| Revenue | 36.27B KRW | KR#1,952/2,436 Sec#59/96 |
| Net Income | 7.07B KRW | KR#1,016/2,436 Sec#30/96 |
| Total Assets | 49.65B KRW | KR#2,192/2,436 Sec#76/96 |
| Net Assets | 41.96B KRW | KR#2,000/2,436 Sec#70/96 |
| Employees | 72 | KR#1,841/2,436 Sec#72/96 |
| Value | ||
| P/E | 5.46x | KR#329/2,436 Sec#5/96 |
| P/B | 0.92x | KR#1,415/2,436 Sec#35/96 |
| PEG | 0.11x | KR#404/2,436 Sec#13/96 |
| P/S | 1.06x | KR#1,437/2,436 Sec#31/96 |
| EV/EBITDA | 3.94x | KR#144/2,436 Sec#5/96 |
| FCF Yield | 16.87% | KR#403/2,436 Sec#5/96 |
| Profitability | ||
| ROE | 16.84% | KR#187/2,436 Sec#10/96 |
| ROA | 14.23% | KR#88/2,436 Sec#9/96 |
| Op. Margin | 23.47% | KR#102/2,436 Sec#8/96 |
| Revenue Growth | 12.43% | KR#834/2,436 Sec#37/96 |
| Earnings Growth | 48.65% | KR#579/2,436 Sec#22/96 |
| Financial Health | ||
| Debt Ratio | 118.32% | KR#619/2,436 Sec#29/96 |
| Total Debt | 3.50B KRW | KR#1,837/2,436 Sec#65/96 |
| FCF | 6.51B KRW | KR#832/2,436 Sec#23/96 |
| Cash | 8.56B KRW | KR#1,759/2,436 Sec#61/96 |
| Current Ratio | 4.31x | KR#367/2,436 Sec#25/96 |
| Net Debt/EBITDA | -0.59x | KR#560/2,436 Sec#21/96 |
| Dividend | ||
| Div. Yield | 2.57% | KR#735/2,436 Sec#12/96 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | 2.84% | KR#651/2,436 Sec#16/96 |
| 1M Return | -2.33% | KR#1,141/2,436 Sec#52/96 |
| From 52W High | -35.24% | KR#578/2,436 Sec#21/96 |
| 1Y MDD | -37.33% | KR#422/2,436 Sec#9/96 |
| Trading | ||
| Volume | 60,420 shares | KR#1,234/2,436 Sec#52/96 |
| Foreign Own. | 3.30% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | 976 KRW | KR#631/2,436 Sec#13/96 |
| BPS | 6,141 KRW | KR#1,287/2,436 Sec#31/96 |
Company Info
The company, established in 2006, was listed on the KOSDAQ market in 2021 through a reverse merger with Kyobo 8th Special Purpose Acquisition Company. It manufactures medical materials, wound dressings, biosensor patches, and cosmetics, primarily supplying polyurethane foam dressings and hydrocolloid dressings to hospitals and pharmacies. Driven by population aging and increasing plastic surgeries, the company is expanding its business into the wound dressing market and developing skin regeneration and functional cosmetics in the derma-cosmetic sector. WonBiogen was established in 2018 and is headquartered in Gumi-si, Gyeongsangbuk-do.